Outcomes of supraflex sirolimus eluting coronary stents
Background: The introduction of Sirolimus Eluting Coronary Stents (SES) was a major breakthrough in interventional cardiology. The large, randomized, clinical trials using SES have shown a remarkable reduction in angiographic restenosis and target vessel revascularization (TVR) compared with bare-me...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Journal of Applied Sciences and Clinical Practice |
| Subjects: | |
| Online Access: | http://www.jascp.org/article.asp?issn=2772-364X;year=2022;volume=3;issue=1;spage=25;epage=31;aulast=Singh |
| _version_ | 1797866463796658176 |
|---|---|
| author | Vishal Virendra Singh Sheikh Mohammad Tahir Sanjiv Sharma |
| author_facet | Vishal Virendra Singh Sheikh Mohammad Tahir Sanjiv Sharma |
| author_sort | Vishal Virendra Singh |
| collection | DOAJ |
| description | Background: The introduction of Sirolimus Eluting Coronary Stents (SES) was a major breakthrough in interventional cardiology. The large, randomized, clinical trials using SES have shown a remarkable reduction in angiographic restenosis and target vessel revascularization (TVR) compared with bare-metal stents as well as other drug-eluting stents (DESs). However, there is only limited data on the outcome of Indian patients treated by DES of Indian origin. The purpose of the study was to evaluate the outcomes of the supraflex sirolimus-eluting coronary stents for the treatment of coronary artery disease and to determine major adverse cardiovascular and cerebrovascular events (MACCE). Materials and Methods: This was a single-centre, observational, nonrandomized study that enrolled unselected real-world patients at a tertiary care center who had undergone implantation with supraflex sirolimus-eluting stents. The primary end-point of the study was MACCE, which is a conglomeration of cardiac death, target lesion revascularization (TLR), TVR, cerebrovascular accident (CVA), and heart failure at 1-year follow-up. Results: A total of 100 patients were intervened successfully with sirolimus-eluting stents. Out of total patients, diabetes and hypertension were observed in 38% and 35% of patients. According to ACC/AHA classification, there were 68% Type B lesions and 32% Type C lesions. At 1-year follow-up, MACE was found to be 11%, which is a composite of 4% TLR, 3% TVR, 1% CVA, and 5% heart failure. Diabetes (P = 0.02), hypertension (P = 0.01), kidney dysfunction (P = 0.002), and LV function (P = 0.01) strongly correlate with outcome (MACCE). Conclusion: There was an acceptable rate of adverse events after implantation of the supraflex sirolimus-eluting stents, although it was slightly higher compared to other studies. Diabetes, hypertension, kidney dysfunction, and LV function strongly correlate with outcome (MACCE). |
| first_indexed | 2024-04-09T23:25:38Z |
| format | Article |
| id | doaj.art-d965b057afa1499295e184a837772576 |
| institution | Directory Open Access Journal |
| issn | 2772-364X 2772-3658 |
| language | English |
| last_indexed | 2024-04-09T23:25:38Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Applied Sciences and Clinical Practice |
| spelling | doaj.art-d965b057afa1499295e184a8377725762023-03-21T11:09:42ZengWolters Kluwer Medknow PublicationsJournal of Applied Sciences and Clinical Practice2772-364X2772-36582022-01-0131253110.4103/jascp.jascp_25_21Outcomes of supraflex sirolimus eluting coronary stentsVishal Virendra SinghSheikh Mohammad TahirSanjiv SharmaBackground: The introduction of Sirolimus Eluting Coronary Stents (SES) was a major breakthrough in interventional cardiology. The large, randomized, clinical trials using SES have shown a remarkable reduction in angiographic restenosis and target vessel revascularization (TVR) compared with bare-metal stents as well as other drug-eluting stents (DESs). However, there is only limited data on the outcome of Indian patients treated by DES of Indian origin. The purpose of the study was to evaluate the outcomes of the supraflex sirolimus-eluting coronary stents for the treatment of coronary artery disease and to determine major adverse cardiovascular and cerebrovascular events (MACCE). Materials and Methods: This was a single-centre, observational, nonrandomized study that enrolled unselected real-world patients at a tertiary care center who had undergone implantation with supraflex sirolimus-eluting stents. The primary end-point of the study was MACCE, which is a conglomeration of cardiac death, target lesion revascularization (TLR), TVR, cerebrovascular accident (CVA), and heart failure at 1-year follow-up. Results: A total of 100 patients were intervened successfully with sirolimus-eluting stents. Out of total patients, diabetes and hypertension were observed in 38% and 35% of patients. According to ACC/AHA classification, there were 68% Type B lesions and 32% Type C lesions. At 1-year follow-up, MACE was found to be 11%, which is a composite of 4% TLR, 3% TVR, 1% CVA, and 5% heart failure. Diabetes (P = 0.02), hypertension (P = 0.01), kidney dysfunction (P = 0.002), and LV function (P = 0.01) strongly correlate with outcome (MACCE). Conclusion: There was an acceptable rate of adverse events after implantation of the supraflex sirolimus-eluting stents, although it was slightly higher compared to other studies. Diabetes, hypertension, kidney dysfunction, and LV function strongly correlate with outcome (MACCE).http://www.jascp.org/article.asp?issn=2772-364X;year=2022;volume=3;issue=1;spage=25;epage=31;aulast=Singhacute coronary syndromedrug-eluting stentspercutaneous coronary interventionpercutaneous coronary intervention outcomes |
| spellingShingle | Vishal Virendra Singh Sheikh Mohammad Tahir Sanjiv Sharma Outcomes of supraflex sirolimus eluting coronary stents Journal of Applied Sciences and Clinical Practice acute coronary syndrome drug-eluting stents percutaneous coronary intervention percutaneous coronary intervention outcomes |
| title | Outcomes of supraflex sirolimus eluting coronary stents |
| title_full | Outcomes of supraflex sirolimus eluting coronary stents |
| title_fullStr | Outcomes of supraflex sirolimus eluting coronary stents |
| title_full_unstemmed | Outcomes of supraflex sirolimus eluting coronary stents |
| title_short | Outcomes of supraflex sirolimus eluting coronary stents |
| title_sort | outcomes of supraflex sirolimus eluting coronary stents |
| topic | acute coronary syndrome drug-eluting stents percutaneous coronary intervention percutaneous coronary intervention outcomes |
| url | http://www.jascp.org/article.asp?issn=2772-364X;year=2022;volume=3;issue=1;spage=25;epage=31;aulast=Singh |
| work_keys_str_mv | AT vishalvirendrasingh outcomesofsupraflexsirolimuselutingcoronarystents AT sheikhmohammadtahir outcomesofsupraflexsirolimuselutingcoronarystents AT sanjivsharma outcomesofsupraflexsirolimuselutingcoronarystents |